Has Nicholas Phreaner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,344 in general payments to Nicholas Phreaner, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nicholas Phreaner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nicholas Phreaner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nicholas Phreaner, MD

Cardiovascular Disease · San Diego, CANPI 1023373040

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by AstraZeneca at 44.3% of the total. Reporting peaked in 2024 at $1,339 and has fallen 89.1% since, to $146 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$2,344in general payments, 2019–2025

Across 42 payments — averaging $55.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$364
Abbott$311
Kestra Medical Technology Services, Inc.$223
Chiesi USA, Inc.$129
Abiomed$75
plus $203 from 6 others

$11,697in research payments, 2019–2025

Across 7 payments — averaging $1671.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Butterfly Network, Inc.$7K
Medtronic$5K

What the payments were for

Consulting fees$91539%
Food & beverage$1,36158%
Education$693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	7	$1,039
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	18	$364
Abbott	2	$311
Kestra Medical Technology Services, Inc.	5	$223
Chiesi USA, Inc.	1	$129
Abiomed	2	$75
Novo Nordisk	1	$62
Philips North America LLC	1	$43
E.r. Squibb & Sons, L.L.C.	2	$33
Scpharmaceuticals Inc.	1	$30
Kiniksa Pharmaceuticals International, PLC	1	$19
Irhythm Technologies, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,344 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$230,282

Medicare patients

1,065

Services billed

2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	278	$348,481
Repatha SureclickEvolocumab	147	$118,293
JardianceEmpagliflozin	86	$105,537
EntrestoSacubitril/Valsartan	59	$79,101
XareltoRivaroxaban	47	$54,939
Praluent PenAlirocumab	32	$17,097
Repatha PushtronexEvolocumab	14	$9,477
Ezetimibe	185	$7,134
Metoprolol Succinate	394	$6,146
Rosuvastatin Calcium	323	$5,586
Atorvastatin Calcium	343	$3,721
Diltiazem 24hr Er (Cd)Diltiazem Hcl	47	$2,370
Spironolactone	177	$1,882
Amlodipine Besylate	262	$1,726
Flecainide Acetate	44	$1,693

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in San Diego

Lori DanielsSan Diego$278K
Michael WilkinsonSan Diego$145K
Ted LoveHillsborough$102.8M
Paul KurthSanta Barbara$6.1M
Jason RogersSacramento$4.4M
Matthew BudoffTorrance$3.6M
Eric Topolla Jolla$2.2M
Cathleen Bairey-MerzLos Angeles$1.2M
Gagan SinghSacramento$1.2M
Pam Taubla Jolla$1.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →